Association between cannabis use and schizotypal dimensions - A meta-analysis of cross-sectional studies

Psychiatry Research

Volumn 219, Issue 1, 2014, Pages 58-66

  Szoke, Andrei ^a,b,c,d   Galliot, Anne Marie ^a,b,e   Richard, Jean Romain ^b,d,e   Ferchiou, Aziz ^a,b,e   Baudin, Grégoire ^a,b,e   Leboyer, Marion ^a,b,c,d,e   Schürhoff, Franck ^a,b,c,d,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM U955   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d FONDATION FONDAMENTAL   (France)

^e Hopital Albert Chenevier   (France)

Author keywords

Psychosis; Review; Schizotypy; Substance related disorders

Indexed keywords

CANNABIS;

CANNABIS USE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISORIENTATION; HUMAN; LONGITUDINAL STUDY; NEGATIVE SCHIZOTYPY; POSITIVE SCHIZOTYPY; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; SCHIZOTYPAL PERSONALITY DISORDER; SYSTEMATIC REVIEW; CANNABIS ADDICTION; CANNABIS SMOKING; COMPLICATION; FEMALE; META ANALYSIS; PSYCHOLOGY;

CANNABIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; PSYCHOMETRICS; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 84902543535     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.05.008     Document Type: Review

References (67)

1. Anglin D.M., Corcoran C.M., Brown A.S., Chen H., Lighty Q., Brook J.S., Cohen P.R. Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophrenia Research 2012, 137:45-49.
2. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. The British journal of psychiatry: The Journal Of Mental Science 2004, 184:110-117.
3. Arthur W., Bennett W., Huffcutt A.I. Conducting Meta-analysis Using SAS 2001, Lawrence Erlbaum Associates, Hillsdale.
4. Bailey E.L., Swallow B.L. The relationship between cannabis use and schizotypal symptoms. European Psychiatry: The Journal of the Association of European Psychiatrists 2004, 19:113-114.
5. Barkus E., Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine 2008, 38:1267-1276.
6. Barkus E.J., Stirling J., Hopkins R.S., Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 2006, 39:175-178.
7. Baskak B., Munir K., Ozguven H.D., Koc E., Gedik G., Erkan D., Atbasoglu C.E. Total exposure duration and proximity of cessation of cannabis use predict severity of sub-clinical psychotic symptoms among former users. Psychiatry Research 2012, 198:316-318.
8. Chapman L.J., Chapman J.P., Raulin M.L. Scales for physical and social anhedonia. Journal of Abnormal Psychology 1976, 85:374-382.
9. Cohen A.S., Buckner J.D., Najolia G.M., Stewart D.W. Cannabis and psychometrically-defined schizotypy: use, problems and treatment considerations. Journal of Psychiatric Research 2011, 45:548-554.
10. Cohen A.S., Davis T.E. Quality of life across the schizotypy spectrum: findings from a large nonclinical adult sample. Comprehensive psychiatry 2009, 50:408-414.
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences 2 1988, Lawrence Erlbaum Associates Inc., Hillsdale.
12. Compton M.T., Chien V.H., Bollini A.M. Associations between past alcohol, cannabis, and cocaine use and current schizotypy among first-degree relatives of patients with schizophrenia and non-psychiatric controls. The Psychiatric Quarterly 2009, 80:143-154.
13. Compton M.T., Goulding S.M., Walker E.F. Cannabis Use, First-Episode Psychosis, and Schizotypy: A Summary and Synthesis of Recent Literature. Current Psychiatry Reviews 2007, 3:161-171.
14. Copeland J., Swift W. Cannabis use disorder: epidemiology and management. International Review of Psychiatry (Abingdon, England) 2009, 21:96-103.
15. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2004, 29:1558-1572.
16. Dumas P., Saoud M., Bouafia S., Gutknecht C., Ecochard R., Dalery J., Rochet T., d'Amato T. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Research 2002, 109:27-35.
17. Earleywine M. Schizotypy, marijuana, and differential item functioning. Human Psychopharmacology 2006, 21:455-461.
18. Eckblad M., Chapman L.J. Magical ideation as an indicator of schizotypy. Journal of Consulting and Clinical Psychology 1983, 51:215-225.
19. Egger M., Schneider M., Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ Clinical Research 1998, 316:140-144.
20. Esterberg M.L., Goulding S.M., McClure-Tone E.B., Compton M.T. Schizotypy and nicotine, alcohol, and cannabis use in a non-psychiatric sample. Addictive Behaviors 2009, 34:374-379.
21. Fleming S., Mallett J., Murphy J., Shevlin M. Traumatic experience, cannabis use, life satisfaction, and schizotypy. Psychosis: Psychological, Social and Integrative Approaches 2012, 4:126-136.
22. Fridberg D.J., Skosnik P.D., Hetrick W.P., O'Donnell B.F. Neural correlates of performance monitoring in chronic cannabis users and cannabis-naive controls. Journal of Psychopharmacology 2013, 27:515-525.
23. Fridberg D.J., Vollmer J.M., O'Donnell B.F., Skosnik P.D. Cannabis users differ from non-users on measures of personality and schizotypy. Psychiatry Research 2011, 186:46-52.
24. GROUP Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Archives of General Psychiatry 2011, 68:138-147.
25. Hall W., Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion In Psychiatry 2007, 20:393-397.
26. Hedges L.V., Olkin I. Statistical Methods for Meta-analysis 1985, Academic Press, Orlando, FL.
27. Heresco-Levy U. Chapter XVII-3: amino acid transmitter systems. Biological Psychiatry 2002, vol. 2:587-600. Wiley, New York.
28. Hides L., Lubman D.I., Buckby J., Yuen H.P., Cosgrave E., Baker K., Yung A.R. The association between early cannabis use and psychotic-like experiences in a community adolescent sample. Schizophrenia Research 2009, 112:130-135.
29. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558.
30. Hill A.B. The environment and disease: association or causation?. Proceedings of the Royal Society of Medicine 1965, 58:295-300.
31. Hollis C., Groom M.J., Das D., Calton T., Bates A.T., Andrews H.K., Jackson G.M., Liddle P.F. Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder ADHD. Schizophrenia Research 2008, 105:216-223.
32. Kendler K.S., Lieberman J.A., Walsh D. The structured interview for schizotypy SIS: a preliminary report. Schizophrenia Bulletin 1989, 15:559-571.
33. Kiang M., Christensen B.K., Streiner D.L., Roy C., Patriciu I., Zipursky R.B. Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study. Psychopharmacology (Berlin) 2013, 225:95-104.
34. Kim D.J., Skosnik P.D., Cheng H., Pruce B.J., Brumbaugh M.S., Vollmer J.M., Hetrick W.P., O'Donnell B.F., Sporns O., Puce A., Newman S.D. Structural network topology revealed by white matter tractography in cannabis users: a graph theoretical analysis. Brain Connectivity 2011, 1:473-483.
35. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T., Tohen M., McGlashan T. The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse. Schizophrenia Research 1996, 20:69-77.
36. Laguerre A., Leboyer M., Schurhoff F. The schizotypal personality disorder: historical origins and current status. L'Encéphale 2008, 34:17-22.
37. Le Bec P.Y., Fatséas M., Denis C., Lavie E., Auriacombe M. Cannabis and psychosis: search of a causal link through a critical and systematic review. L'Encéphale 2009, 35:377-385.
38. Lewandowski K.E., Barrantes-Vidal N., Nelson-Gray R.O., Clancy C., Kepley H.O., Kwapil T.R. Anxiety and depression symptoms in psychometrically identified schizotypy. Schizophrenia Research 2006, 83:225-235.
39. Linscott R.J., van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychological Medicine 2013, 43:1133-1149.
40. Mason O., Claridge G. The Oxford-liverpool inventory of feelings and experiences O-LIFE: further description and extended norms. Schizophrenia Research 2006, 82:203-211.
41. Mason O., Morgan C.J., Dhiman S.K., Patel A., Parti N., Patel A., Curran H.V. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychological Medicine 2009, 39:951-956.
42. Mass R., Bardong C., Kindl K., Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology 2001, 34:209-214.
43. Minozzi S., Davoli M., Bargagli A.M., Amato L., Vecchi S., Perucci C.A. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug and Alcohol Review 2010, 29:304-317.
44. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
45. Morgan C.J., Rothwell E., Atkinson H., Mason O., Curran H.V. Hyper-priming in cannabis users: a naturalistic study of the effects of cannabis on semantic memory function. Psychiatry Research 2010, 176:213-218.
46. Nunn J.A., Rizza F., Peters E.R. The incidence of schizotypy among cannabis and alcohol users. The Journal of Nervous and Mental Disease 2001, 189:741-748.
47. Potvin S., Sepehry A.A., Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine 2006, 36:431-440.
48. Pulay A.J., Stinson F.S., Dawson D.A., Goldstein R.B., Chou S.P., Huang B., Saha T.D., Smith S.M., Pickering R.P., Ruan W.J., Hasin D.S., Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions. Primary Care Companion to the Journal of Clinical Psychiatry 2009, 11:53-67.
49. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin 1991, 17:555-564.
50. Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annual Review of Clinical Psychology 2006, 2:291-326.
51. Reid P.T., Macleod J., Robertson J.R. Cannabis and the lung. The Journal of the Royal College of Physicians of Edinburgh 2010, 40:323-328. (quiz 324-333).
52. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol and Alcoholism (Oxford, Oxfordshire) 2005, 40:2-14.
53. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005, 2:e141.
54. Schaub M., Boesch L., Stohler R. Association between aggressiveness, schizotypal personality traits and cannabis use in Swiss psychology students. Psychiatry Research 2006, 143:299-301.
55. Schiffman J., Nakamura B., Earleywine M., LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Research 2005, 134:37-42.
56. Schubart C.D., van Gastel W.A., Breetvelt E.J., Beetz S.L., Ophoff R.A., Sommer I.E., Kahn R.S., Boks M.P. Cannabis use at a young age is associated with psychotic experiences. Psychological Medicine 2011, 41:1301-1310.
57. Skosnik P.D., Krishnan G.P., Aydt E.E., Kuhlenshmidt H.A., O'Donnell B.F. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. American Journal of Psychiatry 2006, 163:1798-1805.
58. Skosnik P.D., Park S., Dobbs L., Gardner W.L. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry Research 2008, 157:279-282.
59. Skosnik P.D., Spatz-Glenn L., Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 2001, 48:83-92.
60. Stefanis N.C., Hanssen M., Smirnis N.K., Avramopoulos D.A., Evdokimidis I.K., Stefanis C.N., Verdoux H., Van Os J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychological Medicine 2002, 32:347-358.
61. Sterne J.A., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology 2001, 54:1046-1055.
62. Stirling J., Barkus E.J., Nabosi L., Irshad S., Roemer G., Schreudergoidheijt B., Lewis S. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 2008, 41:371-378.
63. Van Dam N.T., Earleywine M., DiGiacomo G. Polydrug use, cannabis, and psychosis-like symptoms. Human Psychopharmacology 2008, 23:475-485.
64. van Gastel W.A., Wigman J.T., Monshouwer K., Kahn R.S., van Os J., Boks M.P., Vollebergh W.A. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. Addiction 2012, 107:381-387.
65. Verdoux H., Sorbara F., Gindre C., Swendsen J.D., van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophrenia Research 2003, 59:77-84.
66. Williams J.H., Wellman N.A., Rawlins J.N. Cannabis use correlates with schizotypy in healthy people. Addiction 1996, 91:869-877.
67. Zaldivar Basurto F., Garcia Montes J.M., Flores Cubos P., Sanchez Santed F., Lopez Rios F., Molina Moreno A. Validity of the self-report on drug use by university students: correspondence between self-reported use and use detected in urine. Psicothema 2009, 21:213-219.